Sponsors / KYTX
KYTX

Kyverna Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
3Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisNCT06193889Kyverna TherapeuticsPhase 2, Phase 3Recruiting2027-09Estimated
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976Kyverna TherapeuticsPhase 2Active not recruiting2027-04Estimated
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromeNCT06588491Kyverna TherapeuticsPhase 2Completed2026-06-25Actual

Latest recorded trial changes

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

NCT06588491 · Kyverna Therapeutics

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

25 participants (planned)

+ After

27 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Jul 2026

+ After

25 Jun 2026

Recruitment status changed

− Before

Active not recruiting

+ After

Completed

Check registry source
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889 · Kyverna Therapeutics

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment Arm to Standard of Care Arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm

+ After

Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

Check registry source